Adiponectin in patients with metabolic syndrome and diseases of the liver, bile ducts and pancreas
Authors:
Adam Vašura; Martin Blaho; Petr Dítě; Tomáš Kupka; Pavel Svoboda; Arnošt Martínek
Authors‘ workplace:
Gastroenterologické oddělení Interní kliniky LF OU a FN Ostrava
Published in:
Vnitř Lék 2017; 63(12): 945-948
Category:
Reviews
Overview
Epidemiological data show that the metabolic syndrome can be diagnosed in up to 30 % of the population. Regarding 5 components of the metabolic syndrome, three of them, in case of positivity (visceral obesity, arterial hypertension, hypertriglyceridemia, changes of HDL-cholesterol levels and type 2 diabetes mellitus), are pathogenic factors which are the most frequently related to cardiovascular diseases, but currently they are also the focus of interest for gastroenterologists. The relationship between non-alcoholic hepatic steatosis, including non-alcoholic steatohepatitis, has been described. Less is known so far about the relation to the pancreas disease, particularly with respect to the status referred to as non-alcoholic fatty pancreas disease. The hormone selectively produced by adipose tissue is adiponectin. This protein is studied as a possible biomarker in people with metabolic syndrome, including obesity. Besides that, there is a question studied whether adiponectin can also play a significant role in the pathogenesis of diseases associated with fat building up in parenchymatous organs. Finding a reliable biomarker for patients with metabolic syndrome or diseases of the liver, biliary system and pancreas in relation to metabolic syndrome, presents a big challenge. And adiponectin is one of the promising biomarkers.
Key words:
adiponectin – biliary disease – metabolic syndrome – pancreatic steatosis – steatohepatitis
Sources
1. Alberti K, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–1645. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192644>.
2. Mokáň M, Galajda P, Prídavková D et al. Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabetes Res Clin Pract 2008; 81(2): 238–242. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2008.04.002>.
3. Mohan V, Deepa R, Pradeepa R et al. Association of low adiponectin levels with the metabolic syndrome – the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005; 54(4): 476–481.
4. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 2014; 28(1):119–130. Dostupné z DOI: <http://dx.doi.org/10.1016/j.beem.2013.08.006>.
5. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68(11): 975–981.
6. Kishida K, Kim KK, Funahashi T et al. Relationships between circulating adiponectin levels and fat distribution in obese subjects. J Atheroscler Thromb 2011; 18(7): 592–595.
7. Kishida K, Funahashi T, Matsuzawa Y et al. Visceral adiposity as a target for the management of the metabolic syndrome. Ann Med 2012; 44(3): 233–241. Dostupné z DOI: <http://dx.doi.org/10.3109/07853890.2011.564202>.
8. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol 2008; 43(11): 811–822. Dostupné z DOI: <http://dx.doi.org/10.1007/s00535–008–2213–6>.
9. Polyzos SA, Toulis KA, Goulis DG et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60(3): 313–326. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2010.09.003>.
10. Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010; 391(9): 1005–1018. Dostupné z DOI: <http://dx.doi.org/10.1515/BC.2010.104>.
11. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1062–1079. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2015.11.006>.
12. Polyzos SA, Toulis KA, Goulis DG et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60(3): 313–326. Dostupné z DOI: <http://dx.doi.org/10.1016/j.metabol.2010.09.003>.
13. Polyzos SA. Kountouras J, Zavos C et al. The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease. Diabetes Obes Metab 2010; 12(5): 365–383. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2009.01176.x>.
14. Van der Poorten D, Samer CF, Ramezani-Moghadam M et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology 2013; 57(6): 2180–2188. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.26072>.
15. Musso G,Bo S, Cassader M et al. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr 2013; 98(4):895–906. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.113.063792>.
16. Zhou YJ, Zhang ZS, Nie YQ et al. Association of adiponectin gene variation with progression of nonalcoholic fatty liver disease: A 4‐year follow‐up survey. J Dig Dis 2015; 16(10): 601–609. Dostupné z DOI: <http://dx.doi.org/10.1111/1751–2980.12288>.
17. Tsai CJ, Leitzmann MF, Willett WC et al. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004; 80(1): 38–44.
18. Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D et al. Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol 2005; 11(11): 1653–1657.
19. Kim HG, Han J. Obesity and pancreatic diseases. Korean J Gastroenterol 2012; 59(1): 35–39.
20. Araki H, Nishihara T, Matsuda M et al. Adiponectin plays a protective role in caerulein-induced acute pancreatitis in mice fed a high-fat diet. Gut 2008; 57(10): 1431–1440. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2007.135665>.
21. Yamada T, Araki H, Watabe K et al. Adiponectin deficiency enhanced the severity of cerulein-induced chronic pancreatitis in mice. Journal of gastroenterology 2010; 45(7): 742–749. Dostupné z DOI: <http://dx.doi.org/10.1007/s00535–010–0205–9>.
22. Sharma A, Muddana V, Lamb J et al. Low serum adiponectin levels are associated with systemic organ failure in acute pancreatitis. Pancreas 2009; 38(8): 907–912. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3181b65bbe>.
23. Tukiainen E, Kylanpaa ML, Ebeling P et al. Leptin and adiponectin levels in acute pancreatitis. Pancreas 2006; 32(2): 211–214.
24. Adrych K, Smoczynski M, Stelmanska E et al. Serum adiponectin and leptin concentrations in patients with chronic pancreatitis of alcoholic and nonalcoholic origin. Pancreas 2008; 36(2): 120–124. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3181561187>.
25. Bao Y, Giovannucci EL, Kraft P et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 2013; 105(2): 95–103. Dostupné z DOI: <http://dx.doi.org/10.1093/jnci/djs474>.
26. Pezzilli R, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? World J Diabetes 2014; 5(4): 415. Dostupné z DOI: <http://dx.doi.org/10.4239/wjd.v5.i4.415>.
27. Van Raalte DH, van der Zijl NJ, Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr Opin Clin Nutr Metab Care 2010; 13(4): 478–485. Dostupné z DOI: <http://dx.doi.org/10.1097/MCO.0b013e32833aa1ef>.
28. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68(11): 975–981.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2017 Issue 12
Most read in this issue
- The current role of warfarin
- Citalopram and QT prolongation
- Drug induced tendon injury
- Unusual history of Wilson disease: a case report and review of the literature